Vitamin D3 receptor


  • Accession: P11473
  • Swissprot: VDR_HUMAN
  • Organism: Homo sapiens
  • Gene: VDR
  • Target class: Nuclear hormone receptor

Drug Relations:

Bioactivity details MOA
The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. Bioactivity details MOA
a topical dermatologic for the treatment of moderate plaque psoriasis Bioactivity details MOA
The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. Bioactivity details MOA
Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24. Some experts recommend maintaining recommended levels of vitamin D intake during the COVID-19 pandemic to maintain bone and muscle health and avoid deficiency. Efficacy of vitamin D supplementation in the prevention or treatment of COVID-19 has not been established. Bioactivity details MOA
decrease of bone density caused by prednisolone was prevented by above cpd; decreases number of osteoclast areas in normal rats; RN given refers to (1alpha,3beta,5Z,7E,22E)-isomer Bioactivity details MOA
an analog of vitamin D for the treatment of osteoporosis Bioactivity details MOA
Bioactivity details MOA
suppressed immunoglobulin production & thymic lymphocyte proliferation in vivo Bioactivity details MOA
A VITAMIN D that can be regarded as a reduction product of vitamin D2. Bioactivity details MOA
Bioactivity details MOA